A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.
Also called NCT07351058
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,600 participants
- Sponsor
- Registry
-
NCT07351058 -
2025-523106-32-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, India, Italy, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07351058. Randomized; double masking; primary purpose treatment. Start 2026-03-23 (actual); primary completion 2028-08-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Acronym
- Enith2
- Condition
- Obesity or Overweight
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Combination product)
- Placebo
- Intervention (Combination product)
- Enicepatide
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct07351058- Content hash
a50fc7c392f997678e878a40e2b89eef67d84d428db9bd88a45cb1c049ef6da2